Abstract
Baroreflex activation therapy (BAT) results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity to the heart via a physiological reflex pathway. In a pilot study in 11 NYHA Class III heart failure (HF) patients, BAT produced a persistent significant reduction of sympathetic activity over 21 months follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA Class III HF patients, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p <0.02). This was associated with a trend toward fewer in-hospital days for HF. BAT might become a powerful tool to repair autonomic alterations due to HF at their origin and thus, profoundly affect the prognosis of advanced HF patients.
| Original language | English |
|---|---|
| Pages (from-to) | 559-569 |
| Number of pages | 11 |
| Journal | Interventional Cardiology |
| Volume | 7 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 1 2015 |
Fingerprint
Keywords
- Autonomic nervous system
- Baroreflex
- Heart failure
- Nonpharmacologic therapy
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Baroreflex activation therapy for the treatment of heart failure. / Gronda, Edoardo; Vanoli, Emilio.
In: Interventional Cardiology, Vol. 7, No. 6, 01.12.2015, p. 559-569.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Baroreflex activation therapy for the treatment of heart failure
AU - Gronda, Edoardo
AU - Vanoli, Emilio
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Baroreflex activation therapy (BAT) results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity to the heart via a physiological reflex pathway. In a pilot study in 11 NYHA Class III heart failure (HF) patients, BAT produced a persistent significant reduction of sympathetic activity over 21 months follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA Class III HF patients, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p <0.02). This was associated with a trend toward fewer in-hospital days for HF. BAT might become a powerful tool to repair autonomic alterations due to HF at their origin and thus, profoundly affect the prognosis of advanced HF patients.
AB - Baroreflex activation therapy (BAT) results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity to the heart via a physiological reflex pathway. In a pilot study in 11 NYHA Class III heart failure (HF) patients, BAT produced a persistent significant reduction of sympathetic activity over 21 months follow-up and a dramatic decrease in the number and length of hospitalizations. In a multinational, prospective, randomized, parallel-controlled, clinical trial in 146 NYHA Class III HF patients, BAT produced a significant N-terminal pro-brain natriuretic peptide reduction (p <0.02). This was associated with a trend toward fewer in-hospital days for HF. BAT might become a powerful tool to repair autonomic alterations due to HF at their origin and thus, profoundly affect the prognosis of advanced HF patients.
KW - Autonomic nervous system
KW - Baroreflex
KW - Heart failure
KW - Nonpharmacologic therapy
UR - http://www.scopus.com/inward/record.url?scp=84948148017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948148017&partnerID=8YFLogxK
U2 - 10.2217/ica.15.44
DO - 10.2217/ica.15.44
M3 - Article
AN - SCOPUS:84948148017
VL - 7
SP - 559
EP - 569
JO - Interventional Cardiology Review
JF - Interventional Cardiology Review
SN - 1756-1477
IS - 6
ER -